» Articles » PMID: 21209785

A Roadmap to the Brittle Bones of Cystic Fibrosis

Overview
Journal J Osteoporos
Publisher Wiley
Specialty Orthopedics
Date 2011 Jan 7
PMID 21209785
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Cystic fibrosis (CF) is an autosomal recessive disorder which despite advances in medical care continues to be a life-limiting and often fatal disease. With increase in life expectancy of the CF population, bone disease has emerged as a common complication. Unlike the osteoporosis seen in postmenopausal population, bone disease in CF begins at a young age and is associated with significant morbidity due to fractures, kyphosis, increased pain, and decreased lung function. The maintenance of bone health is essential for the CF population during their lives to prevent pain and fractures but also as they approach lung transplantation since severe bone disease can lead to exclusion from lung transplantation. Early recognition, prevention, and treatment are key to maintaining optimal bone health in CF patients and often require a multidisciplinary approach. This article will review the pathophysiology, current clinical practice guidelines, and potential future therapies for treating CF-related bone disease.

Citing Articles

Mathematical models of cystic fibrosis as a systemic disease.

Olivenca D, Davis J, Kumbale C, Zhao C, Brown S, McCarty N WIREs Mech Dis. 2023; 15(6):e1625.

PMID: 37544654 PMC: 10843793. DOI: 10.1002/wsbm.1625.


External validity of machine learning-based prognostic scores for cystic fibrosis: A retrospective study using the UK and Canadian registries.

Qin Y, Alaa A, Floto A, van der Schaar M PLOS Digit Health. 2023; 2(1):e0000179.

PMID: 36812602 PMC: 9931238. DOI: 10.1371/journal.pdig.0000179.


Nutritional Care in Children with Cystic Fibrosis.

Mariotti Zani E, Grandinetti R, Cunico D, Torelli L, Fainardi V, Pisi G Nutrients. 2023; 15(3).

PMID: 36771186 PMC: 9921127. DOI: 10.3390/nu15030479.


Bisphosphonates for osteoporosis in people with cystic fibrosis.

Jeffery T, Chang A, Conwell L Cochrane Database Syst Rev. 2023; 1:CD002010.

PMID: 36625789 PMC: 9831115. DOI: 10.1002/14651858.CD002010.pub5.


Lung parenchymal calcifications in a child with cystic fibrosis.

Lynch H, Qian F, Wong M, Thomas R, Kapur N Respirol Case Rep. 2022; 10(5):e0941.

PMID: 35386578 PMC: 8968259. DOI: 10.1002/rcr2.941.


References
1.
Hardin D, Leblanc A, Marshall G, Seilheimer D . Mechanisms of insulin resistance in cystic fibrosis. Am J Physiol Endocrinol Metab. 2001; 281(5):E1022-8. DOI: 10.1152/ajpendo.2001.281.5.E1022. View

2.
Jacquot J, Tabary O, Clement A . Hyperinflammation in airways of cystic fibrosis patients: what's new?. Expert Rev Mol Diagn. 2008; 8(4):359-63. DOI: 10.1586/14737159.8.4.359. View

3.
Papaioannou A, Kennedy C, Freitag A, Ioannidis G, ONeill J, Webber C . Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS trial). Chest. 2008; 134(4):794-800. PMC: 5104558. DOI: 10.1378/chest.08-0608. View

4.
Gardner J, van Bezooijen R, Mervis B, Hamdy N, Lowik C, Hamersma H . Bone mineral density in sclerosteosis; affected individuals and gene carriers. J Clin Endocrinol Metab. 2005; 90(12):6392-5. DOI: 10.1210/jc.2005-1235. View

5.
Centrella M, McCarthy T, Canalis E . Activin-A binding and biochemical effects in osteoblast-enriched cultures from fetal-rat parietal bone. Mol Cell Biol. 1991; 11(1):250-8. PMC: 359615. DOI: 10.1128/mcb.11.1.250-258.1991. View